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Abstract
Intermittent application of parathyroid hormone (PTH) has well established anabolic effects on bone mass in rodents and
humans. Although transcriptional mechanisms responsible for these effects are not fully understood, it is recognized that
transcriptional factor cAMP response element binding protein (CREB) mediates PTH signaling in osteoblasts, and that there
is a communication between the PTH-CREB pathway and the BMP2 signaling pathway, which is important for osteoblast
differentiation and bone formations. These findings, in conjunction with putative cAMP response elements (CREs) in the
BMP2 promoter, led us to hypothesize that the PTH-CREB pathway could be a positive regulator of BMP2 transcription in
osteoblasts. To test this hypothesis, we first demonstrated that PTH signaling activated CREB by phosphorylation in
osteoblasts, and that both PTH and CREB were capable of promoting osteoblastic differentiation of primary mouse
osteoblast cells and multiple rodent osteoblast cell lines. Importantly, we found that the PTH-CREB signaling pathway
functioned as an effective activator of BMP2 expression, as pharmacologic and genetic modulation of PTH-CREB activity
significantly affected BMP2 expression levels in these cells. Lastly, through multiple promoter assays, including promoter
reporter deletion, mutation, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift assay (EMSA), we
identified a specific CRE in the BMP2 promoter which is responsible for CREB transactivation of the BMP2 gene in
osteoblasts. Together, these results demonstrate that the anabolic function of PTH signaling in bone is mediated, at least in
part, by CREB transactivation of BMP2 expression in osteoblasts.
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Introduction
Parathyroid hormone (PTH) plays an important role in skeletal
metabolism. In mice [1–4] and rats [5,6], intermittent adminis-
tration of PTH has anabolic effects on bone mass and bone
formation. Similarly, when PTH is administered intermittently to
humans, it has been proven to increase bone mass and decrease
fracture risk in post-menopausal women, elderly men, and women
with glucocorticoid-induced osteoporosis [7–10]. Despite its
clinical efficacy, the precise molecular mechanisms responsible
for the anabolic effects of PTH on bone, particularly at the
transcriptional level, need to be further elucidated.
Although multiple intracellular signaling mechanisms are
involved in mediating PTH function, the major downstream
signaling pathway of PTH in bone cells involves 59-cyclic adenosine
monophosphate (cAMP), protein kinase A (PKA), and cAMP
response element binding protein (CREB). The anabolic function of
this cAMP-PKA-CREB pathway in bone has been characterized in
vivo and in vitro [11–30]. Increasing activity of this pathway promotes
osteoblast differentiation [11–26] and stimulates bone formation
[27–30]. In osteoblasts, PTH binds to a PTH receptor and induces
formation of cAMP, leading to activation of PKA, which in turn
phosphorylates and activates CREB, a member of a large family of
basic leucine zipper (bZIP) domain DNA-binding proteins [11–14].
Activated CREB, in association with the other co-activators, binds
to target genes through a cAMP response element (CRE) and
activates their transcription. Therefore, in this pathway, CREB
plays a pivotal role by converting the PTH signal to activation of
gene expression. In various cell systems, CREB induces the
expression of some osteoblast-related genes, such as bone
sialoprotein (BSP) and osteocalcin (OCN), by directly binding to
these promoters [13–22]. However, the major downstream targets
of CREB transactivation, which have a predominant role in
initiating osteoblast differentiation and stimulating bone formation,
are unknown.
Bone morphogenetic protein 2 (BMP2) is an important growth
factor that stimulates osteoblast differentiation and bone formation
[31–33]. The PTH-cAMP-CREB signaling pathway synergizes
the anabolic signaling of BMP2 for osteoblast differentiation and
bone formation [23,25,26,28,29,34], indicating that there is a
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signaling pathways. Recently, we have reported that osteoblast-
specific deficiency of CREB in mice causes reduction of postnatal
bone mass and decreases BMP2 expression in osteoblasts [35,36],
suggesting that BMP2 could be a critical transcriptional target of
CREB in osteoblasts. This is consistent with the findings of a
genome-wide study, based on a chromatin immunoprecipitation
(ChIP) assay, in which the cAMP-CREB signaling pathway was
identified as a positive transcriptional regulator of BMP2 mRNA
expression in PC12 cells [37]. Furthermore, we have identified
multiple CREs in the BMP2 promoter by DNA sequence analysis.
Based on the collective findings reviewed above, it is reasonable to
hypothesize that the transcription factor CREB is an activator of
BMP2 expression in osteoblasts, and that CREB mediates the
anabolic function of PTH-cAMP signaling in bone, at least in part,
by this mechanism. This hypothesis was examined in the current
investigation through pharmacological and genetic experiments,
and promoter analyses.
Results
PTH signaling activates CREB in osteoblasts
CREB activity is controlled by phosphorylation through
multiple signaling pathways, including the PTH signaling pathway
[11–14]. Here, we determined the effects of manipulating the
signaling activity of the PTH-cAMP-signaling cascade on CREB
phosphorylation in osteoblasts. First, we determined the effect of
PTH on CREB phosphorylation in osteoblasts. Pluripotent
mesenchymal precursor C2C12 cells, which are capable of
differentiating into an osteoblast lineage, were treated with PTH,
and phosphorylation levels of CREB were detected by Western
blot, with non-phosphorylated CREB and b-actin as controls. The
results showed that treatment with PTH at 0–500 nM substan-
tially, and dose-dependently, increased CREB phosphorylation
(Fig. 1A). The minimum dose with a discernable effect was
approximately 50 nM (Fig. 1A). The PTH-induced CREB
phosphorylation in osteoblasts was also time-dependent between
5 and 60 minutes (Fig. 1B). As a second messenger, cAMP is
known to mediate PTH signaling. Thus, we determined the effects
of the cAMP enhancer 3-isobutyl-1-methylxanthine (IBMX), an
inhibitor of cAMP phosphodiesterase, on CREB phosphorylation.
Western blot showed that incubation of C2C12 cells with IBMX at
doses of 10–300 mM increased intracellular levels of phosphory-
lated CREB protein (Fig. 1C), and that this stimulation was
induced in a time-dependent manner up to 4 hours (Fig. 1D). As a
direct downstream target of cAMP, PKA phosphorylates CREB.
Next, we examined the effects of inhibition of PKA activity on
CREB phosphorylation using KT5720, a PKA inhibitor. We
found that the KT5720-induced inhibition of PKA activity
markedly reduced levels of phosphorylated CREB in C2C12 cells,
in both dose- and time-dependent manners (Fig. 1E, 1F). The
levels in the Western blot of phosphor-CREB treated by IBMX
and KT5720 were quantitated. The quantitative results confirmed
that these cAMP and PKA drugs dose- and time-dependently
regulated CREB phosphorylation in osteoblasts (see the quantita-
tive data in Figure S1).
Phosphorylated CREB migrates into nuclei and transactivates
target genes through CRE binding sites. Consequently, we
evaluated the effects of PTH, which induces CREB phosphoryla-
tion, on transcriptional activity of CREB. The luciferase assay using
a CREB-specific reporter CRE-Luc showed that overexpression of
CREBinC2C12 cellsdose-dependently increasedtheactivity ofthe
CRE reporter, and that treatment with PTH at 50 nM further
elevated the CREB-induced reporter activity (Fig. 1G).
PTH-CREB pathway promotes osteoblast differentiation
It has been postulated that the anabolic effect of PTH on bone is
mediated through osteoblasts. In this series of experiments, we
characterized the role of the PTH-CREB signaling pathway in
osteoblast differentiation. First, we determined the effects of PTH
on alkaline phosphatase (ALP) activity of C2C12 cells by
incubating cells with PTH for 24 hours. Measurement of ALP
activity in cell lysates showed that treatment with PTH at 0–
200 nM stimulated ALP activity in a pattern that approached
dose-dependence, with a maximum effect (2-fold increase) at PTH
concentration 100 nM (Fig. 2A). Real time PCR showed that the
mRNA levels of osteoblast maturation genes, Runx2 and type I
collagen 1a1 (Col1a1), were significantly enhanced by treatment
with PTH at doses of 10–100 nM (Fig. 2B).
Then, we determined the effects of overexpression of CREB on
osteoblast differentiation. Osteoblast precursor C2C12 and 2T3
cells [38–40] were transfected with CREB expression plasmid or
its empty vector for 48 hours. Enzymatic quantitation of ALP
activity showed that CREB overexpression significantly increased
ALP activity in both C2C12 and 2T3 cells, compared with vehicle
controls (Fig. 2C). Interestingly, CREB-stimulation of ALP activity
was completely reversed in these cells by adding noggin (500 ng/
ml), a natural BMP antagonist, to the culture medium (Fig. 2C).
This finding is critical evidence for our hypothesis that the
stimulatory effect of CREB on ALP depends on BMP signaling.
mRNA measurement of C2C12 cells also showed that CREB
transfection significantly increased expression of osteoblast-specific
marker genes, including Runx2, Col1a1 and osteocalcin (OCN)
(Fig. 2D). Next, we determined whether overexpression of CREB
affects bone matrix formation in osteoblast precursor 2T3 cells,
which can form mineralized matrices in culture under osteogenic
conditions [33,37–40]. Von Kossa staining showed that mineral-
ized bone nodule formation was greatly enhanced in 2T3 cell
cultures 14 and 21 days after CREB transfection, compared with
control 2T3 cells transfected with empty vector (Fig. 2E).
In order to confirm the role of CREB in promoting osteoblast
differentiation, we performed a loss-of-function study with primary
CREB-deficient calvarial osteoblast cells. These cells were isolated
from conditional CREB knockout mice (CREB cKO), that were
generated by crossing CREB floxed mice with Col1a1-Cre mice.
We have recently reported that these osteoblast-specific CREB
knockout mice exhibit low bone mass [35,36]. In the present study,
we found that CREB deficiency markedly decreased both basal
and PTH-induced ALP activity in calvarial osteoblast cells,
compared with floxed control cells (Fig. 2F). We also noticed
that, despite at a much lower level than PTH treatment in the
control group, PTH appeared still capable of increasing ALP
activity in the absence of CREB, compared with vehicle treatment.
However, the statistical analysis did not show a significant
difference between the treatment groups in the CREB deficient
cells. This suggests that PTH stimulation of ALP activity was
attenuated by removal of the CREB gene in the calvairal
osteoblast cells, (Fig. 2F). Together, these results suggest that the
PTH-CREB pathway is an activator of osteoblast differentiation.
PTH up-regulates BMP2 expression through CREB in
osteoblasts
The finding that noggin blocked CREB-induced ALP activity in
osteoblasts (Fig. 2C) suggested an involvement of the BMP
pathway in CREB function. A previous genome-wide study has
found that BMP2, a prototype member of the BMP family, is a
transcriptional target of the CREB pathway in other cell systems
[37]. Given these facts, and the presence of potential
CREB binding elements in the BMP2 promoter (vide infra), we
CREB Activates BMP2 Expression in Osteoblasts
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least in part, by up-regulating BMP2 transcription in osteoblasts.
To test this hypothesis, we first examined the effects of PTH on
BMP2 expression. C2C12 cells were incubated with PTH at
0–200 nM for 12 hours, and real time PCR was performed to
quantitate BMP2 mRNA levels. The results showed that PTH
treatment increased BMP2 mRNA expression in a dose-dependent
manner (Fig. 3A). We also found that stimulation of BMP2 mRNA
expression by PTH (50 nM) was time-dependent from 0 to
12 hours (Fig. 3B). In BMP2 promoter assays, C2C12 cells were
transfected with a mouse BMP2 promoter reporter, 22712/+165-
Luc [38–40], and cultured in the presence or absence of PTH.
The promoter reporter luciferase assays showed that treatment
with PTH for 24 hours increased BMP2 promoter activity
(Fig. 3C), further demonstrating that PTH is an activator of
BMP2 transcription in osteoblasts.
Next, we determined the effects of drugs, IBMX and KT5720
that regulate PTH signaling activity, on BMP2 promoter
activity. C2C12 cells that carry the BMP2 promoter reporter
were transfected with CREB expression vector, and then treated
with these drugs. We found that CREB transfection substan-
tially increased BMP2 promoter activity, and that treatment
with the cAMP enhancer IBMX further increased CREB
stimulation. In contrast, treatment with the PKA inhibitor
KT5720 significantly decreased CREB-induced BMP2 pro-
moter activity (Fig. 3D).
Figure 1. PTH signaling activates CREB phosphorylation in osteoblasts. (A–F) CREB phosphorylation levels in C2C12 cells, treated with PTH
at 0 to 500 nM for 1 hour (A); PTH at 50 nM for 5 to 60 min (B); or IBMX at 0 to 300 mM for 1 hour (C); IBMX at 50 mM for 0 to 4 hours (D); or KT5720 at
0t o1 0mM for 1 hour (E); KT5720 at 10 mM for 0 to 2 hours (F), were detected by Western blot with anti-phosphorylated CREB antibody, with
normalization by non-phosphorylated CREB and b-actin. (G) C2C12 cells were co-transfected with CRE-Luc reporter and CREB expression vector, and
treated with PTH at 50 nM for 36 hours. The reporter luciferase activity was measured with normalization by b-gal activity. # p,0.01 (CREB vs vector;
mean6SE, n=6); * p,0.05 (PTH vs vehicle; mean6SE, n=6).
doi:10.1371/journal.pone.0020780.g001
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transcription in the absence of CREB using the CREB-deficient
calvarial cells described above. We found that CREB deficiency
significantly reduced BMP2 mRNA levels compared with the control
cells (Fig. 3E, black bars) and that the stimulation of BMP2 expression
by treatment with PTH (50 nM) for 24 hours was largely abolished
by inactivation of CREB in the CREB-deficient cells, compared with
the control cells (Fig. 3E, gray bars). These data indicate that PTH
signaling acts as an upstream stimulator of BMP2 gene expression in
osteoblasts, and that this function is mediated through CREB.
CREB activates BMP2 transcription in osteoblasts
We have shown that overexpression of CREB enhanced BMP2
promoter activity (Fig. 3D). To fully characterize the activating
Figure 2. PTH-CREB pathway promotes osteoblast differentiation. (A) ALP activity in C2C12 cells, treated with PTH at 0 to 200 nM for
24 hours, was measured with normalization by cell proteins. * p,0.05 (vs vehicle; mean6SE, n=8). (B) mRNA levels of Runx2 and Col1a1 in C2C12
cells, treated with PTH for 12 hours, were quantitated by real time PCR, normalized by 18S rRNA. * p,0.01 (vs vehicle; mean6SE, n=6). (C) ALP
activity in C2C12 and 2T3 cells was measured after transfection with CREB expression plasmid and treated with noggin at 500 nm/ml for 48 hours.
*p ,0.01 (CREB vs vector); # p,0.05 (noggin vs vehicle; mean6SE, n=8). (D) mRNA levels of Runx2, Col1a1 and OCN in C2C12 cells, transfected with
CREB for 24 hours, were measured by real time PCR, normalized by 18S rRNA. * p,0.05 (vs vector; mean6SE, n=6). (E) 2T3 cells were transfected
with vector (top) or CREB plasmid (bottom) and cultured under osteogenic conditions for 14 and 21 days. Von Kossa staining was performed to
visualize the mineralized matrix formation. (F) Isolated calvarial osteoblastic cells from newborn conditional CREB knockout mice (CREB cKO) and their
CREBfloxed littermate controls were cultured for 24 hours and ALP activity was measured. * p,0.05 (cKO vs control); # p,0.05 (PTH on cKO vs PTH
on control); ** p,0.05 (PTH va vehicle on control mice; mean6SE, n=6); NS: not significant.
doi:10.1371/journal.pone.0020780.g002
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gain- and loss-of-function experiments to determine the effects of
manipulating CREB levels on BMP2 gene expression in
osteoblasts. We found that overexpression of CREB in osteoblastic
cell lines, including C2C12, 2T3 and UMR106 cells, substantially
increased BMP2 mRNA levels in these cells, compared with vector
controls (Fig. 4A). Next, we evaluated the effects of CREB
transfection on BMP2 promoter activity. The luciferase assay with
22712/+165-Luc reporter showed that CREB markedly
increased transcriptional activity of the BMP2 promoter in these
osteoblastic cells, with a maximal stimulation of approximately
15-fold in C2C12 cells (Fig. 4B). In contrast, small interfering
RNA (siRNA) knockdown of endogenous CREB in these
osteoblast cell lines had significant inhibitory effects on BMP2
Figure 3. PTH up-regulates BMP2 expression through CREB. (A, B) BMP2 mRNA levels in C2C12 cells, treated with PTH at 0 to 200 nM for
12 hours (A); or PTH at 50 nM for 0 to 12 hours (B), were measured by real time PCR with GAPDH normalization. * p,0.01 (vs vehicle; mean6SE,
n=6). (C) BMP2 promoter reporter activity in C2C12 cells, transfected with 22712/+165-Luc and treated with PTH at 0 to 200 nM for 24 hours, was
measured with b-gal normalization. * p,0.01 (vs vehicle; mean6SE, n=8). (D) BMP2 promoter reporter activity in C2C12 cells, co-transfected with
CREB plasmid or vector and reporter 22712/+165-Luc, and treated with IBMX at 50 mM or KT5720 at 5 mM for 24 hours, was measured. * p,0.01
(CREB vs vector); # p,0.01 (CREB+IBMX vs CREB+vehicle); ** p,0.05 (CREB+KT5720 vs CREB+vehicle; mean6SE, n=8). (E) BMP2 mRNA levels in
calvrial cells, isolated from CREB cKO and control mice, and treated with PTH at 50 nM for 24 hours, were measured by real time PCR. * p,0.01 (cKO
vs control); # p,0.01 (PTH on cKO vs PTH on control); ** p,0.05 (PTH vs vehicle on control mice; mean6SE, n=6); NS: not significant.
doi:10.1371/journal.pone.0020780.g003
CREB Activates BMP2 Expression in Osteoblasts
PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e20780mRNA transcription, measured by real time PCR, compared with
siRNA controls (Fig. 4C). The loss-of-function by siRNA was
further confirmed by CREB knockout. mRNA quantitation
demonstrated that an osteoblast-specific CREB deletion markedly
reduced BMP2 mRNA levels in primary calvarial osteoblastic
cells, compared with cells isolated from control mice (Fig. 4D).
In addition to CREB and BMP2, other members of the CREB
and BMP families also are involved in osteoblast function. The
Figure 4. CREB activates BMP2 expression. (A) BMP2 mRNA levels in C2C12, 2T3 and UMR106 cells, transfected with CREB plasmid or vector for
24 hours, were measured by real time PCR with GAPDH106 cells. * p,0.01 (vs vector; mean6SE, n=6). (B) BMP2 promoter activity in C2C12, 2T3 and
UMR106 cells, co-transfected with 22712/+165-Luc and CREB plasmid for 24 hours, was measured by luciferase activity with b-gal normalization.
*p ,0.01 (vs vector; mean6SE, n=8). (C) BMP2 mRNA levels in C2C12, 2T3 and UMR106 cells, transfected with CREB siRNA or control siRNA for
36 hours, were measured by real time PCR. * p,0.05 (vs control siRNA; mean6SE, n=6). (D) BMP2 mRNA levels in calvarial cells of CREB cKO and
control mice were measured by real time PCR. * p,0.01 (vs control; mean6SE, n=6). (E) BMP2 promoter reporter activity in C2C12 cells,
co-transfected with 22712/+165-Luc and CREB or ATF4 plasmid for 24 hours, was measured. * p,0.01 (vs vector; mean6SE, n=8). (F) BMP2
promoter reporter activity in C2C12 cells, co-transfected with 22712/+165-Luc or BMP4-Luc and CREB plasmid for 24 hours, was measured. * p,0.01
(vs vector; mean6SE, n=8).
doi:10.1371/journal.pone.0020780.g004
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transcription factor 4 (ATF4) and BMP4. In order to test the
specificity of the effects of CREB on BMP2 expression, we
examined the effects of ATF4 on BMP2 expression and the effects
of CREB on BMP4 expression. The factor ATF4 belongs to the
same large bZIP family of transcription factors as CREB, and has
proven to be important for osteoblast differentiation [41,42]. We
found that, compared with CREB stimulation, ATF4 transfection
did not affect BMP2 promoter activity in C2C12 cells (Fig. 4E). In
the BMP family, BMP4 is structurally closest to BMP2. Using a
BMP4 promoter reporter, BMP4-Luc, we found that, CREB failed
to enhance BMP4 promoter activity, in contrast to CREB
enhancement of BMP2 promoter activity (Fig. 4F). Collectively,
these results strongly support the conclusion that the transcrip-
tional factor CREB is a specific and potent enhancer of BMP2
gene expression in osteoblasts.
CREB transactivates BMP2 through CRE in the BMP2
promoter
CREB is known to transactivate target genes through a specific
CRE consensus sequence in their promoters [17–22]. Sequence
analysis revealed multiple CREs throughout the mouse BMP2
promoter from 22712 to +165 (data not shown). To identify the
functional CRE(s) responsible for CREB transactivation of the
BMP2 promoter, we first performed a promoter deletion study.
C2C12 cells were transiently co-transfected with CREB expression
plasmid or empty vector plus a series of truncated BMP2 promoter
reporters representing 22712/+165, 22457/+165, 2199/+165,
21803/+165, 2968/+165, 2838/+165, 2310/+165, and 2150/
+165 of the 59 promoter region of the BMP2 gene. Interestingly,
we found that none of these progressively truncated BMP2
promoter reporters lost or reduced their responsiveness to CREB
transactivation of luciferase activity (Fig. 5A). These results suggest
that the potential CREs may be located within the 2150/+165
region of the BMP2 promoter. Next, we analyzed the sequence of
this narrow region in the promoter, and identified three putative
CREs (CRE1, CRE2 and CRE3) in this area (Fig. 5B). To
determine the role of these putative CREs in CREB transactiva-
tion, we performed site-directed mutagenesis. Each of these
putative CREs located within the BMP2 promoter-luciferase
construct (2150/+165-Luc) was mutated by deleting or replacing
core nucleotides as shown in figure 5C. The results of luciferase
reporter assays showed that levels of BMP2 transcriptional activity
induced by CREB were comparable for mutant CRE1 and CRE3
reporters (mCRE1 and mCRE3) and the wild-type 2150/+165-
Luc reporter (Fig. 5D). Mutation of CRE2 (mCRE2), however,
resulted in complete abrogation of the response to CREB
stimulation (Fig. 5D), indicating that CRE2, in region 2150/
+165 of the BMP2 promoter, is a functional CRE responsible for
CREB’s action on the BMP2 gene. Furthermore, we also
examined the effects of CRE2 mutation on PTH stimulation of
BMP2 promoter activity. As shown in Figure 5E, we found that
PTH lost its stimulatory effect on BMP2 promoter activity when
the CRE2 is mutated, compared with wild-type CRE2 control.
We subsequently performed ChIP and EMSA assays to verify the
interaction of CREB with CRE2 in the BMP2 promoter. In the
ChIP assay, a 230 bp fragment of the BMP2 promoter containing
the specific CRE2 sequence was amplified after the addition of anti-
CREB antibody to nuclear DNA-protein complexes extracted from
C2C12 cells, compared with non-specific IgG control (Fig. 5F, lane
3 vs lane 2). This suggests that CREB binds directly to CRE2 in the
BMP2 promoter. Importantly, treatment of these cells with PTH
(50 nM) for 6 hours further increased CREB binding ability to
CRE2,evidencedbyincreasedPCRproduct inthegel (Fig.5F,lane
4 vs lane 3). Furthermore, EMSA was performed to obtain direct
evidence ofphysical bindingofCREBwith CRE2.Nuclear proteins
were extracted from C2C12, 2T3 and MC3T3-E1 osteoblast cells
and reacted with a biotin-labeled DNA probe containing the CRE2
sequence (213 to +20) of the BMP2 promoter. The addition of the
CRE2 probe to these cell extracts induced a shift in mobility of the
probe in the gel, (Fig. 5G, lane 2–4 vs lane 1), indicating a direct
interaction between the CRE2 probe and nuclear proteins. Further,
addition of anti-CREB antibody to the reaction mixture of C2C12
cells produced a super shift in mobility of the band (Fig. 5G, lane 7
vs lane 6), indicating that CREB binds directly to this CRE2
complex. Based onthe combined results of luciferase reporter,ChIP
and EMSA assays, we propose that the transcriptional factor CREB
transactivates the BMP2 gene through a specific CRE2 site in the
BMP2 promoter.
Discussion
These collective results provide evidence that the PTH signaling
pathway is an effective activator of BMP2 gene expression in
osteoblasts, and this function is mediated by CREB transactivation
of the BMP2 promoter. This transcriptional mechanism, at least in
part, accounts for the anabolic function of the PTH-CREB
pathway in osteoblast differentiation and bone formation.
It is well documented that intermittent dosing with PTH has an
anabolic effect on bone [1–10], and that the PTH signaling
pathway is a physiological regulator of osteoblast function in bone
[11–30]. As a major mediator of PTH signaling, the transcrip-
tional factor CREB has been found to play a role in osteoblast
differentiation by regulating expression of osteoblast-specific genes
[13–22], by which CREB may function as an anabolic regulator
for bone mass. Several previous in vivo studies have provided
evidence for the anabolic function of CREB in bone
[30,35,36,43,44]. A recent report showed that small molecules
with potent osteogenic activity induce osteoblast differentiation by
activating intracellular CREB activity [43]. In studies with Lrp 5
knockout mice that exhibit low bone mass, Yadav et al reported
that Lrp5 deficiency increases duodenal production of serotonin,
which inhibits osteoblast function by suppressing CREB activity in
osteoblasts [44]. Furthermore, they found that Lrp5 and CREB
double knockout mice have a significantly lower bone mass than
Lrp5 single null mutants [44]. Recently, we have reported that
osteoblast-specific knockout of CREB in mice produces a skeletal
phenotype with low bone mineral density and low bone volume
[35,36]. This is consistent with a previously reported similar
osteopenic phenotype of the osteoblast-specific ICER (inducible
cAMP early repressor) transgenic mice [30]. ICER belongs to the
same bZIP family of transcription factors as CREB, and acts as a
dominant negative regulator of gene transcription through CRE.
Thus, it appears that CREB plays an important role in postnatal
bone formation through its effect on osteoblast cells. To explore
the mechanisms by which CREB exerts its effects on bone, in the
current gain- and loss-of-function studies employing primary
osteoblast cells and multiple osteoblast cell lines, we found that
manipulation of activity and expression levels of PTH and CREB
affects osteoblast function. We also demonstrated that the PTH-
CREB signaling pathway is a positive regulator of osteoblast
differentiation. These findings further support the hypothesis that
promoting osteoblast differentiation is one of cellular mechanisms
by which the PTH-CREB signaling pathway exerts its anabolic
function in bone.
The cAMP-PKA-CREB axis represents a major signaling
pathway that mediates PTH signaling [11–30]. In the current
study, we demonstrated that PTH induces CREB phosphorylation
CREB Activates BMP2 Expression in Osteoblasts
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e20780Figure 5. CREB transactivates BMP2 through CRE in the BMP2 promoter. (A) BMP2 promoter reporter activity in C2C12 cells, co-transfected
with CREB plasmid and a series of truncated reporter constructs for 24 hours, was measured with b-gal normalization. (B) Sequence of 2150/+165 of
mouse BMP2 promoter. Putative sequences for CRE1, CRE2 and CRE3 are underlined and bolded. Sequences of ChIP primers are underlined only.
(C) Sequences of mutant CRE1, CRE2 and CRE3 (mCRE1, mCRE2 and mCRE3). (D) BMP2 promoter reporter activity in C2C12 cells, co-transfected with
wild-type 2150/+165-Luc (WT) and mutant 2150/+165-Luc in which CREs were mutated (mCRE1, mCRE2 and mCRE2), and with CREB plasmid for
24 hours, was measured. * p,0.01 (CREB transfection on mCRE2 vs WT or mCRE1 or mCRE3 reporters; mean6SE, n=8). (E) Effects of PTH on BMP2
promoter activity. C2C12 cells were co-transfected with wild-type 2150/+165-Luc (WT) and mutant 2150/+165-Luc in which CRE2 was mutated
(mCRE2) and treated with PTH at 50 nM for 24 hours. * p,0.01 (PTH mCRE2 vs PTH on WT reporter; mean6SE, n=8).F) ChIP assay. Nuclear DNA-
protein complexes were extracted from C2C12 cells treated with PTH at 50 nM for 6 hours and precipitated with anti-CREB antibody. PCR was
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ical manipulation of the PTH signaling cascade in the upstream of
CREB. The results of experiments with the cAMP-enhancer and
the PKA-inhibitor suggest that the capacity of CREB to enhance
BMP2 transcription in osteoblasts is phosphorylation-dependent.
In these studies, however, we found that the PKA-inhibitor
(KT5720) failed to completely abolish the capacity of CREB to
increase BMP2 transcription in osteoblasts, suggesting that other
protein kinases, in addition to PKA (such as protein kinase C), also
may be involved in this process. Similar results have been reported
with other cell systems [45,46]. In a separate experiment, we found
that the cAMP-enhancer IBMX had biphasic effects on the BMP2
promoter, depending on the duration of treatment. In contrast to
the stimulatory effect on BMP2 expression observed in this study
when cells were exposed to IBMX for only 24 hours, extending
exposure up to 48 hours resulted in inhibition of BMP2 promoter
activity (data not shown). This latter effect of IBMX on the BMP2
gene may be due to the degradation of transcription factor Gli2,
which we previously identified as a stimulator of BMP2 expression
in osteoblasts [39,40].
CREB transactivates target genes through a consensus cAMP
response element (CRE), by which CREB has been shown to
transactivate multiple osteoblast maturation related marker genes,
such as BSP and OCN [13–22]. The rationale in this study to
focus on the BMP2 gene as a critical transcriptional target of
CREB in osteoblasts includes the following: (1) BMP2 is the
prototypic member of the BMP family responsible for osteoblast
differentiation; (2) cAMP, an upstream activator of CREB, up-
regulates BMP2 gene expression in other cells [37], and; (3)
multiple putative CRE sites can be found throughout the BMP2
promoter. Therefore, we mapped out the molecular interaction
between CREB protein and the BMP2 promoter. Utilizing
promoter deletion, mutation, ChIP and EMSA studies, we defined
a specific CRE (CRE2) located within the basal promoter loci
from 2150 to +165, as a functional binding element responsible
for CREB transactivation of the BMP2 gene. We recognize,
however, that regulation of the BMP2 gene is complex, and that
multiple additional mechanisms, involving Gli proteins [39,40,47],
b-catenin/TCF [48] and ERa [49], have been reported to
contribute to the regulation of BMP2 transcription. Thus, we do
not exclude the possibility that additional untested CRE sequences
in the upstream of the BMP2 promoter may also possess potential
cis-functions in BMP2 gene transcription in response to other
nuclear transcription factors such as those identified above.
Interestingly, in this study, we found that ATF4 (a member of
the CREB/ATF family) failed to stimulate BMP2 expression. In
other cell types, ATF4 and CREB have been shown to share the
same DNA binding element (TGACGTCA) in transactivating the
promoter activities of target genes [49]. We presume, therefore,
that CREB transactivation of the BMP2 gene in osteoblasts may
require other co-activators associated within the CREB transcrip-
tional machinery that are structurally and functionally distinct
from those associated with ATF4 action. However, more
comparison studies about the transcriptional mechanisms of these
factors on the BMP2 gene are needed to examine this possibility.
The experiments in which noggin blocked CREB-induced ALP
activity support the concept that the function of CREB in
osteoblasts is likely BMP-dependent, because noggin blocks BMP
signaling by hindering BMP ligands from binding to BMP
receptors [50,51]. The present data showed that CREB, as a
powerful stimulator of BMP2 transcription, lacks the capability to
induce expression of BMP4, the closest member of BMP2 in the
BMP family. However, it is possible that CREB may have a
positive regulating function for transcription of other BMP family
members. This possibility warrants further investigation.
In addition to the capability of increasing BMP2 gene
expression in osteoblasts demonstrated in the current study, the
PTH-cAMP-CREB pathway also has been shown to enhance
BMP2 activity. For example, it has been demonstrated that this
pathway is capable of enhancing BMP2-stimulated Smad signaling
[34], and synergizing the BMP2-induced anabolic effects on
differentiation of osteoblasts [23,25,26] and chondrocytes [23,52]
in vitro, and new bone formation in vivo [28,29]. In contrast, BMP2
is also known to have a positive feedback effect on CREB function.
In osteoblast precursor C2C12 cells, BMP2 synergizes with PKA-
CREB to enhance ALP activity [25]. Therefore, the crosstalk
between the PTH-CREB and BMP2 signaling pathways is
complex, and could occur at multiple steps in these signaling
cascades. In order to further test the role of BMP2 in mediating
the function of PTH-CREB signaling in osteoblast differentiation
and bone formation, a BMP2 invalidated mouse model is needed.
We are now proposing a study using osteoblast-specific BMP2
knockout mice to determine the effects of BMP2 deficiency on the
anabolic effects of intermittent PTH on bone mass. The present
finding that PTH-CREB up-regulates of BMP2 gene expression in
osteoblasts provides new insights into the relation between these
important anabolic signaling pathways in bone.
In summary, the functional and mechanistic studies in this study
demonstrate that PTH signaling is a positive regulator of BMP2
gene expression in osteoblasts, mediated directly by CREB
transactivation of BMP2 promoter activity. This transcriptional
mechanism contributes to osteoblast differentiation. The collective
results of these studies support the hypothesis that the anabolic
effects of PTH on bone mass are mediated through the cAMP-
PKA-CREB-BMP2 pathways.
Materials and Methods
DNA constructs and compounds
The CREB expression plasmid pRC/RSV-CREB, its empty
vector pRC/RSV, and CREB responsive reporter (CRE-Luc)
containing multiple CREs were obtained from Dr. Richard
Goodman [53]. The ATF4 expression vector was a gift of Dr.
Xiangli Yang [42]. Mouse BMP2 promoter luciferase reporter
(22712/+165-Luc) was constructed by linking the 59 promoter
region (22712/+165) of mouse the BMP2 gene to firefly luciferase
in a pGL3 vector [39–40]. The promoter was truncated from the
distal end by enzymatic digestion to create a series of deletion
constructs, including 22457/+165-Luc, 2199/+165-Luc,
21803/+165-Luc, 2968/+165-Luc, 2838/+165-Luc, 2310/
+165-Luc, and 2150/+165-Luc. Mouse BMP4 promoter reporter
(BMP4-Luc) was obtained from Dr. Stephen Harris. The CREB
siRNA (CREB ShortCutH siRNA Mix), and negative control
siRNA (New England Biolabs, Beverly, MA), IBMX and KT5720
(Calbiochem, San Diego, CA), and PTH and noggin (R&D
Systems, Minneapolis, MN), was purchased.
performed to amplify the region of the BMP2 promoter that contained CRE2, using PCR primers indicated in (B). Input: BMP2 promoter DNA. IgG:
Goat IgG as a negative control. (G) EMSA assay. Nuclear extracts of C2C12, 2T3 and MC3T3-E1 cells were incubated with a biotin-labeled DNA probe
containing the CRE2 binding site sequence in the BMP2 promoter, in the absence or presence of anti-CREB antibody. The shift and super shift bands
were analyzed using a 5% polyacrylamide gel.
doi:10.1371/journal.pone.0020780.g005
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lines
Osteoblastic cell lines: C2C12 (ATCC, #CRL-1772), 2T3
[54], UMR106 (ATCC, #1661), and MC3T3-E1 (ATCC,
#2593) cells were seeded into 6 to 48-well plates with complete
culture media (DMEM for C2C12 and UMR106 cells and
aMEM for 2T3 and MC3T3-E1 cells), supplemented with 10%
fetal calf serum (FCS), 1% penicillin/streptomycin and 1%
L-Glutamine, at a cell density that allowed cells to reach 60–70%
confluence after overnight culture in 5% CO2 at 37uC. Calvarial
osteoblastic cells: Calvarial bones were dissected from newborn
osteoblast-specific CREB knockout mice and their control
littermates. CREB knockout mice, which exhibit low bone mass
[35,36], were generated by crossing CREBfloxed mice [55] with
type I collagen I-a ´1 Cre (Col1a1-2.3-Cre) mice. These mice were
housed following standard LAR mouse housing protocol. All the
mouse manipulations were performed under a Tulane IACUC
approved protocol (#4196). Calvarial tissues were digested with
0.05% trypsin and 1.5 U/ml collagenase at 37uC on a rocking
platform. Cell fractions 2 to 4 were collected and cultured in
aMEM.
CREB phosphorylation assay
C2C12 cells cultured in 6-well plates were incubated with PTH,
IBMX or KT5720 at different doses for 0 to 4 hours. Cells were
lysed with SDS-RIPA buffer containing protease inhibitors PMSF
(1 mM), aprotinin (10 mg/ml) and leupeptin (10 mg/ml). Samples
were loaded on SDS-PAGE (Mini-Protein II Ready Gels,
Bio-Rad, Hercules, CA), and proteins were electrophoretically
separated under reducing conditions and then transferred onto
PVDF membranes (Bio-Rad) in transblotting buffer (25 mM Tris,
192 mM glycine and 20% [v/v] methanol, pH 8.3) at 4uC for
1 hour. After blocking with 5% milk in TBS-T (0.1% Tween 20)
for 1 hour at room temperature, membranes were incubated with
antibodies against phosphorylated-CREB (Phospho-CREB,
Ser133) or non-phosphorylated CREB (Cell Signaling Technology
Inc. Danvers, MA) in 5% milk in TBS-T at 4uC overnight. After
washes, membranes were incubated with horse-radish peroxidase
(HRP)-conjugated secondary antibody (Amersham Biosciences,
Buckinghamshire, UK) at 1:5,000 dilution at room temperature
for 1 hour, then washed 6 times with TBS-T buffer for 5 minutes
each. Immunoblots were detected using an enhanced chemilumi-
nesence ECL system (Amersham). The antibodies on the same
PVDF membranes were removed with stripping buffer and re-
blotted with anti-b-actin antibody to detect b-actin levels for
protein normalization.
Alkaline phosphatase (ALP) activity assay
All the tested osteoblast cells were seeded into 48-well plates. To
test the effects of PTH, C2C12 cells were incubated with PTH at
different doses for 24 hours. To test the effects of CREB
overexpression, C2C12 and 2T3 cells were transiently transfected
with CREB expression vector or empty vector using LipofectA-
mine Plus reagent (Invitrogen, Carlsbad, CA) following the
manufacturer’s protocol. The transfected cells were cultured in
the presence or absence of noggin at 500 ng/ml for 48 hours. To
test the effects of CREB knockout, primary calvarial cells were
harvested and cultured for 24 hours. All these cells were cultured
in media supplemented with 2.5% FCS. Then, cells were lysed in
0.05% Triton X-100 buffer. ALP activity in cell lysates was
spectrophotometrically quantitated at 405 nm using Sigma ALP
reagents (Sigma-Aldrich, St. Louis, MO) and normalized with
total cellular protein.
Mineralized matrix formation
Osteoblastic 2T3 cells were transfected with CREB expression
vector or empty vector in 24-well plates and cultured with aMEM
with 10% FCS. At confluence, the culture medium was
supplemented with 5% FCS, ascorbic acid (100 mg/ml), and
b-glycerol phosphate (5 mM). The medium was refreshed every
other day. At days 14 and 21, the cultures were terminated and
fixed in phosphate-buffered formalin for 10 minutes followed by
von Kossa staining with 2% silver nitrate solution, and exposed to
sunlight for 20 minutes. The area of mineralized matrix was
stained black in the wells.
Real time PCR
Total RNA was purified from osteoblast cells in 6-well plates with
various treatments, and reverse transcribed into cDNA. Quantitative
PCRofmouseBMP2mRNAwasperformedusingacDNAtemplate
and mouse BMP2 primers/probe, Mm01340178_m1 (Applied
Biosystems, Carlsbad,CA) on 7300 Real TimePCR System (Applied
Biosystems). The endogenous control was GAPDH detected using a
VIC/MGB Probe (4352339E, Applied Biosystems). mRNA levels of
other osteoblast marker genes including Runx2, Col1a1 and OCN
were also quantitated by real time PCR using primers
Mm00501578_m1, Mm00801666_g1*, Mm03413826_mH (Ap-
plied Biosystems) respectively, with 18s rRNA for normalization.
Promoter reporter assay
C2C12 cells in 24-well plates were transfected with 0.5 mgo f
CREB responsive reporter CRE-Luc, or mouse BMP2 promoter
luciferase reporter 22712/+165-Luc, or its truncated forms, or
mouse BMP4 promoter reporter BMP4-Luc, and 0.1 mg of pSV-
b-Galactosidase (b-Gal) expression vector (Promega, Madison,
WI), using the LipofectAmine Plus Reagent (Invitrogen). Cells
transfected with the BMP2 or BMP4 promoter reporters were
also co-transfected with 0.2 mg of CREB or ATF4 expression
constructs. The cells were cultured in the presence or absence of
experimental compounds including PTH, IBMX or KT5720 for
24–48 hours and then lysed with Reporter Lysis Buffer (Promega).
Luciferase activities of cell lysates were measured by a luciferase
reporter assay kit (Promega) and normalized to b-Gal activity.
RNA interference
C2C12, 2T3 and UMR106 cells cultured in 6-well plates were
transiently transfected with CREB siRNA or negative control
siRNA (CREB ShortCutH siRNA Mix, New England Biolabs)
using siRNA transfection reagents. Following confirmation of
CREB protein levels in the cell lysates by Western blot at 24 to
48 hours after transfection (data not shown), BMP2 mRNA levels
were determined as described above.
Mutation of promoter binding sites
The putative CREs in the BMP2 promoter reporter construct
2150/+165-Luc were mutated by deleting or replacing core
nucleotides using GeneEditor
TM in Vitro Site-Directed Mutagenesis
System (Promega) following the manufacturer’s protocol. The phos-
phorylated mutant primers for individual mutation of CRE1, CRE2
and CRE3 were p-tcgcggcccagctagcagaacgtccgtc, p-ctggtccctgagg-
ccggatccagc agcagccttgcc, and p-cctgctcgaggctgtggatccagcacttggctg-
gag, respectively. The luciferase activity of mutant reporters
responding to CREB transfection were measured as described above.
Chromatin immunoprecipitation (ChIP)
C2C12 cells cultured in 100 mm Petri dishes were incubated
with PTH at 50 nM for 6 hours. The cells were fixed with 1%
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ChIP assay was performed following the protocol of the ChIP kit
(Upstate, MA). Briefly, cells were scraped and sonicated on ice to
shear chromatin DNA down to 0.2–1.0 kb fragments. The
sonicated cell supernatants were pre-cleared with a Protein A
agarose/salmon sperm DNA slurry. Anti-CREB antibody (Cell
Signaling Technology, Inc.) was added to the supernatant at 4uC
overnight, followed by incubation with fresh Protein A agarose
beads for 1 hour at 4uC for precipitation. The specific protein-
DNA complex was disassociated and DNA fragments were
purified. With these DNA fragments as templates, PCR was
performed using primers F-59ggcatcgcccacgatggctg and R-59caa-
gttcaagaagtctcc, to amplify a sequence containing a specific CRE
in the BMP2 promoter. The BMP2 promoter DNA input was used
as a positive control. Goat IgG served as a negative control.
Electrophoresis mobility shift assay (EMSA)
C2C12, 2T3, and MC3T3-E1 cells (approximate 2–4610
6)
were collected by digestion, and the nuclear extracts were
prepared using a kit (Pierce). A synthesized, biotin-labeled and
annealed DNA probe (59tggtccctgaggccgacgacagcagcagccttgc) at
20 fmols, which contained the CRE2 binding site sequence in the
BMP2 promoter, was reacted with nuclear extracts for 20 minutes.
The reactions were applied onto 5% polyacrylamide gels (Bio-
Rad), and then transferred to Nylon membranes. Biotin-labeled
DNA was detected using a streptavidin-horseradish peroxidase
conjugate and chemiluminescent substrate (Pierce). To examine
super shift of DNA-protein complexes, an antibody against CREB
was added to DNA-protein binding reactions and loaded to the
gels. The detailed methods followed the protocol of LightShift
Chemiluminescent EMSA Kit (Pierce).
Statistical analysis
Student’s two-tailed unpaired t test was used to examine the
significance changes in these experiments.
Supporting Information
Figure S1 Quantitation of phosphor-CREB. Cq-Fq: Quan-
titation of phosphor-CREB. C2C12 cells were treated with IBMX
at 0 to 300 mM for 1 hour (Cq); IBMX at 50 mM for 0 to 4 hours
(Dq); or KT5720 at 0 to 10 mM for 1 hour (Eq); KT5720 at
10 mM for 0 to 2 hours (Fq). Phospho-CREB was detected by
Western blot. The signal intensity of Western blot band was
quantitated using GelScan v 5.1 (BioSciTech) with normalization
by the intensity of b-actin.
(TIF)
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